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Abstract
Silicone implants have been used for cosmetic enhancement and reconstructive purposes for over 60 years.
Despite assiduous efforts to ensure safety, there is continuous evidence that they are not as biologically
inert as previously postulated. We present two cases of autoimmune syndrome induced by adjuvants (ASIA)
in Hispanic women. The first patient developed biopsy-proven immune-mediated necrotizing myopathy that
was successfully treated with the combination of silicone explantation along with immunosuppressive
therapy. Findings after implant removal demonstrated rupture and leakage of silicone from gluteal implants.
The second patient developed autoimmune hemolytic anemia in the setting of a ruptured silicone breast
implant. Similarly, the patient was treated with corticosteroids followed by breast implant removal with
complete resolution of symptoms. The successful treatment of these patients was achieved by collaboration
between rheumatology and plastic surgery, which emphasizes the need for a multidisciplinary approach in
the diagnosis and management of patients with ASIA.

Categories: Plastic Surgery, Allergy/Immunology, Rheumatology
Keywords: autoimmune hemolytic anemia, silicone breast implants, immune mediated necrotizing myopathy, breast
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Introduction
The use of silicone implants has been in practice since 1962 for cosmetic enhancement and reconstructive
purposes [1]. The chemical structure and bioengineering of prosthetic breast implants continuously evolve
to achieve the best safety and patient satisfaction and to avoid long-term complications [2]. Despite
assiduous efforts, there is more evidence that silicone implants are not as biologically inert as previously
postulated [3]. The emergence of breast implant illness (BII) or autoimmune syndrome induced by adjuvants
(ASIA), composed of a vast array of clinical manifestations and immune abnormalities, led to a developing
field of research that can only be further expanded by collaboration between plastic surgeons,
rheumatologists, and immunologists.
We present two cases of silicone implant-associated autoimmunity disorder in which the implants' removal
in combination with immunosuppressive medications led to cessation of disease.

Case Presentation
Case 1
The patient was a 55-year-old Hispanic female with a history of breast and gluteal augmentation
with silicone implants 24 years before presentation, followed by the exchange of breast silicone implants for
saline implants 10 years afterward. She was referred to rheumatology by plastic surgery service for
evaluation of autoimmune disorder secondary to silicone implants. Two years prior to the current
presentation, and approximately 22 years after the original breast and gluteal implant augmentation, the
patient developed paresthesia, Raynaud's phenomenon, dysphagia, and progressive proximal muscle
weakness. The patient’s family history was notable for diabetes mellitus in her brother and mother, and
there was no known history of any connective tissue or rheumatic diseases in the family. Physical
examination was remarkable for objective proximal muscle weakness and active Raynaud's phenomenon.
She had no sclerodermatous skin changes, rashes, or cuticular changes, and nailfold capillaroscopy was
negative for vascular abnormalities. The patient was found to have elevated creatine phosphokinase (CPK),
aldolase, and liver enzymes, and she had an initial positive antinuclear antibodies (ANA) of 1:640 with a
nuclear pattern. The 11 myositis-specific antibodies panel was negative (Table 1).
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Parameter

Result

Reference Range

ANA

1:640

< 1:40

Anti-dS-DNA Ab

<1 IU/mL

< 10 IU/mL

Anti-Smith Ab

<1 IU/mL

< 10 IU/mL

Complement C3

81 mg/dL

87-200 mg/dL

Complement C4

18 mg/dL

19-52 mg/dL

CRP

4.69 mg/dL

< 1.0 mg/dL

Anti-histone Ab

< 1 IU/mL

< 25 IU/mL

Anti-Scl 70-Ab

< 7.0 U/mL

< 7.0 U/mL

Anti-SS-A Ab

< 7.0 U/mL

< 7.0 U/mL

Anti-SS-B Ab

< 7.0 U/mL

< 7.0 U/mL

Anti-centromere

< 7.0 U/mL

< 7.0 U/mL

Anti-U1RNP Ab

<1 U/mL

< 5.0 U/mL

Aldolase

59.9 unit/L

< 8.1 unit/L

CPK

5596 IU/L

30-223 IU/L

Myoglobin

1220 mcg/L

<66 mcg/L

AST

128 IU/L

13-39 IU/L

ALT

176 IU/L

7-52 IU/L

Anti-actin Ab

<20 IU/mL

<20 IU/mL

Anti-mitochondrial Ab

< 20 IU/mL

< 20 IU/mL

ESR

15 mm/h

0 to 22 mm/h

Anti- Pl-12 Ab

<11 IU/L

<11 IU/L Negative

Anti- Pl-7 Ab

<11 IU/L

<11 IU/L Negative

Anti- EJ Ab

<11 IU/L

<11 IU/L Negative

Anti-Jo-1 Ab

<11 IU/L

< 11 IU/L Negative

Anti- SRP Ab

<11 IU/L

<11 IU/L Negative

Anti- HMGCR Ab

<11 IU/L

<11 IU/L Negative

Anti-OJ Ab

<11 IU/L

<11 IU/L Negative

Anti-Mi-2 Alpha Ab

<11 IU/L

<11 IU/L Negative

Anti-Mi-2 Betta ab

<11 IU/L

<11 IU/L Negative

Anti-MDA-5 ab

<11 IU/L

<11 IU/L Negative

Anti-Tif-1 Gamma ab

<11 IU/L

<11 IU/L Negative

Anti-NXP-2 ab

<11 IU/L

<11 IU/L Negative

TABLE 1: IMNM rheumatological laboratory studies at presentation
ANA: antinuclear antibody; ds: double stranded; Ab: antibody; CRP: C-reactive protein; SS: Sjögren's syndrome; Scl: scleroderma; U1RNP: small nuclear
ribonucleoprotein; CPK: creatine phosphokinase; AST: aspartate transaminase; ALT: alanine transaminase; ESR: erythrocyte sedimentation rate; SRP:
signal recognition particle; HMGCR: 3-hydroxy-3-methylglutaryl-CoA reductase; MDA-5: melanoma differentiation-associated protein 5; NXP-2: nuclear
matrix protein; IMNM: immune-mediated necrotizing myopathy

MRI of the thighs demonstrated signal abnormality in the posterior muscular compartment suggestive of
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myositis. Subsequently, the patient underwent muscle biopsy, which was remarkable for type 1 fiber
predominance with atrophic type 2 muscle fibers and necrotic fibers with myophagocytosis, leading to a
diagnosis of immune-mediated necrotizing myopathy (IMNM). The patient underwent treatment with
prednisone 1 mg/kg and two months of intravenous immunoglobulins (IVIG) with only mild improvement of
symptoms. Due to concern for ASIA, the patient underwent explantation of breast and buttock implants six
months after the diagnosis of IMNM. While the saline breast implants were intact, bilateral silicone gluteal
implants were ruptured (Figure 1). Both right and left gluteal tissue and capsule show skeletal muscle with
scattered inflammatory cells (Figure 2). During dissection of the left buttock, a small area of murky,
brownish-white fluid was found and was submitted to pathology for microbiology and cytology. The results
of pathology revealed amorphous debris and mixed inflammatory cells and macrophages. Fluid cultures
were negative. Around the time of explantation, the patient was re-evaluated by rheumatology and was
started on mycophenolate mofetil (MMF) up to 1 gm twice daily and intramuscular steroids weekly with
modest improvement of symptoms.

FIGURE 1: Gross pathology of bilateral silicone gluteal implants
demonstrating fragmentation
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FIGURE 2: Histolopathology from gluteal implant demonstrating
fibroadipose capsular tissue and skeletal muscle with scattered
inflammatory cells

The patient continued to manifest muscle weakness and significant gastrointestinal symptoms, including
heartburn, early satiety, abdominal distention, constipation, occasional nausea, and vomiting. She was
further diagnosed with failure to thrive and pneumatosis intestinalis due to small intestinal bacterial
overgrowth (SIBO). She was managed with prokinetics, including metoclopramide, erythromycin, and
rifaximin. She was started on intravenous immunoglobulin (IVIG) 1 gm/kg X 2 days monthly and IV
corticosteroids, 1 mg/kg in divided doses. Due to severe weight loss, she underwent percutaneous
gastrostomy (PEG) placement and was started on TPN. Nine months after explantation, she continues with
MMF and IVIG monthly and has tapered off corticosteroids. Muscle strength has improved progressively, she
no longer has Raynaud's phenomenon, and she is demonstrating continuous improvement of GI symptoms,
tolerating a soft diet and continuing total parenteral nutrition (TPN) intermittently. CPK and aldolase
returned to normal and repeat ANA and 11 myositis panels remained negative on multiple occasions.

Case 2
A 73-year-old Hispanic female with a history of silicone breast augmentation for cosmetic purposes 18 years
before the presentation was referred to rheumatology with a diagnosis of autoimmune hemolytic anemia
(AIHA). The patient did not have a family history of autoimmune conditions but did have a strong family
history of cancer including a father with lung cancer, a sister with breast cancer, and a brother with gastric
cancer. The patient first noticed swelling in the supraclavicular area and developed "big lumps" on the top of
the clavicle that started eight months before the presentation. She mentioned the lumps were intermittently
"turning very red." The mammogram was remarkable for several scattered echogenic masses casting
posterior snowstorm artifacts identified along the right infraclavicular soft tissues, axilla, and internal
mammary chain consistent with extracapsular silicone with rupture suspected. MRI of the breast was
remarkable for right breast implant rupture with silicone lymphadenitis (Figure 3). The patient underwent
fine needle aspiration of supraclavicular mass for cytology. Specimen comprised a few mixed acute and
chronic inflammatory cells, macrophages, and amorphous granular debris. No malignant cells were
identified. The fluid was negative for silicone particles. The patient was diagnosed with AIHA given a direct
antiglobulin test (DAT) that was IgG positive, and C3D positive, and underwent extensive hematologic
workup for etiological diagnosis of AIHA (Table 2). The patient was managed for AIHA with prednisone 1
mg/kg and was further referred to rheumatology. Clinically, she did not manifest symptoms worrisome for
connective tissue disease.
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FIGURE 3: MRI of the breast was remarkable for right breast implant
rupture with silicone lymphadenitis (White arrow)

Parameter

Result

Reference Range

Hemoglobin

8.4 gm/dL

10.8 gm/dL

Hematocrit

25.9 %

32.2 %

MCV

109.3 fl

84 fl

Percent reticulocyte

18.08 %

0.7- 2.8%

Absolute reticulocyte

0.47 m/uL

0.00-0.15 m/uL

Total bilirubin

3.2 mg/dL

0.2 -1.2 mg/dL

Indirect bili

2.4 mg/dL

0.2 -1.2 mg/dL

Haptoglobin

< 8 mg/dL

43-212 mg/dL

LDH

526 IU/L

140-271 IU/L

B 12 Level

250 nmol/L

DAT

IgG positive, CD3 positive

SPEP

No monoclonal protein present

Peripheral blood smear

RBC with numerous microspherocytes and polychromatophilic cells

TABLE 2: AIHA case hematologic labs at presentation
MCV: mean corpuscular volume; LDH: lactate dehydrogenase; DAT: direct antiglobulin test; SPEP: serum protein electrophoresis; AIHA: autoimmune
hemolytic anemia

ANA was positive with a titer of 1:1280 by IF. Another autoimmune workup was negative (Table 3). A repeat
ANA by immunofluorescence was positive with a titer of 1:320 by IF and anti-histone antibodies were
negative. Given the patient's clinical presentation along with the timing of the silicone breast rupture, a
diagnosis of ASIA was made, and the removal of silicone implants was recommended. The patient underwent
the procedure, and the biopsy was consistent with a right collapsed silicone breast implant while microscopy
revealed benign fibroadipose (capsular) tissue, patchy inflammation, focal fat necrosis, and focal foreign
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body giant cell reaction (Figures 4, 5, 6). There was no evidence of malignancy and the left breast had an
intact-unruptured silicone implant (Figure 5). One week after explantation, corticosteroids were
discontinued, the patient did not require additional treatment, and her hemoglobin and hematocrit
improved postoperatively to 12.5 gm/dL and 35.1 % and remained stable 17 months post-explantation.

Parameter

Result

Reference Range

ANA

1:1280

< 1:40

Anti-dS-DNA Ab

0.6 IU/mL

< 10 IU/mL

Anti-histone Ab

< 1.0 unit

ANCA screen

Negative

Negative

Anti-MPO Ab

<1.0 AI

< 1.0 AI

Anti-PRO-3 ab

<1.0 AI

< 1.0 AI

Complement C3

102 mg/dL

87-200 mg/dL

Complement C4

18 mg/dL

19-52 mg/dL

CRP

0.6 mg/dL

< 1.0 mg/dL

Anti-TPO ab

<4.0 IU/mL

< 25 IU/mL

Anti-Jo-1 ab

<0.3 U/mL

< 7.0 U/mL

Anti-Scl70-ab

0.8 U/mL

< 7.0 U/mL

Anti-SS-A ab

0.4 U/mL

< 7.0 U/mL

Anti-SS-B ab

<0.3 U/mL

< 7.0 U/mL

Anti-Centromere

4.8 U/mL

< 7.0 U/mL

Anti-U1RNP ab

1.6 U/mL

< 5.0 U/mL

Anti-RNP-70 ab

<0.3 U/mL

< 7.0 U/mL

Anti-Mi-2 ab

<20.0 unit

<20.0 unit

TABLE 3: AIHA case rheumatological labs at presentation
ANA: antinuclear antibody; ds: double stranded; Ab: antibody; CRP: C-reactive protein; SS: Sjögren's syndrome; Scl: scleroderma; U1RNP: small nuclear
ribonucleoprotein; ANCA: antineutrophil cytoplasmic antibodies; MPO: Myeloperoxidase; RNP: ribonucleoprotein; AIHA: autoimmune hemolytic anemia

2022 Loftis et al. Cureus 14(10): e30397. DOI 10.7759/cureus.30397

6 of 10

FIGURE 4: Gross pathology demonstrating bilateral breast implant with
capsule

FIGURE 5: Gross pathology demonstrating right collapsed open capsule
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FIGURE 6: Right breast implant and capsule tissue (magnification X 20)
showing patchy inflammation, focal fat necrosis, and focal foreign body
cell reaction around silicone particles

Discussion
Silicone polymers were introduced in plastic and reconstructive surgery in 1962, but the first report of their
use was as a waterproof wound dressing in 1947 [4]. Polymers of silicone have been designed as a material
immunologically inert and provide a consistency similar to human tissues [5]. However, more recent data
demonstrate that silicone implants are not as innocuous as initially theorized [3].
While local host reactions secondary to silicone breast implants, including capsule formation, capsular
contracture, implant rupture, and local pain, are well described in plastic and reconstructive surgery
literature, the characterization of systemic autoimmune reactions associated with silicone remains under
scientific grapple. From the rheumatology perspective, some patients with known autoimmune conditions
have been retrospectively identified to have undergone silicone implants [6]. The implant could have been a
potential trigger of autoimmunity in genetically predisposed individuals. Of note, patients frequently omit
to include cosmetic procedures in their past medical history as these are considered elective and not for
medical purposes [4]. Although plastic surgeons are well-versed in diagnosing and managing local reactions
associated with silicone implants, they might not be as familiar with the systemic effects of silicone.
While plastic surgery literature coins the term breast implant illness (BII), the immunology and medical
literature often uses the term ASIA and classifies the autoimmune reaction secondary to silicone under the
ASIA umbrella. Silicone implant incompatibility syndrome is another term used in the literature to describe
this condition [7].
Given the myriad clinical presentations, discordant nomenclature, and lack of definitive classification
criteria for the syndrome, diagnosis and management may present a dilemma for both specialties. This
article described two patients with a history of silicone implant augmentation that developed an
autoimmune condition, successfully co-managed with collaborative efforts from rheumatology, pathology,
radiology, and plastic surgery.
The first patient had initial silicone breast and gluteal implants 24 years before the presentation and
exchange for saline breast implants 10 years before the presentation. She was diagnosed with immunemediated necrotizing myopathy. The disease remained active even after the explantation of breast and
gluteal implants. She required an intense and prolonged immunosuppressive regimen lasting for
approximately six months in order to achieve remission. The second patient had an 18-year history of
silicone implants and presented with AIHA, which required corticosteroid treatment and removal of
ruptured silicone implants. AIHA remained in remission without any immunosuppression 17 months post
explantation and did not require any treatment post explantation.
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Patients with ASIA can present with multiple non-specific complaints, including fatigue, sleep disturbances,
cognitive impairment, arthralgias, myalgias, dry eyes and mouth, rashes, and fever that fail to reach the
criteria for a defined rheumatological disease. Other patients have clear clinical and serologic
manifestations that can be classified as Sjogren's syndrome, systemic sclerosis, rheumatoid arthritis, or
sarcoidosis [8,9]. As per the literature, only a few reported cases of AIHA and respectively inflammatory
myopathy have been associated with silicone implants [10,11].
The patient with IMNM was initially managed with immunosuppressive medications with minimal
improvement. Due to the concern of ASIA, the decision to remove all implants was made. The gluteal
implants were fragmented (Figure 1), and the breast saline implants were intact. Similarly, in the second
case, the AIHA was diagnosed concomitantly with silicone implant rupture that manifested with intense
local reaction. (Figure 3, 6)
As the implant shell elastomer ages, it eventually fails, leading to "silicone bleeding," described as the
migration of low molecular silicone core particles through the high molecular silicone shell. Furthermore,
the shell rupture facilitates this process [8,12,13]. The presence of polydimethylsiloxane has been identified
at sites distant from the implant [13]. In our patient with AIHA, the imaging studies identified silicone in the
right infraclavicular soft tissues, axilla, and internal mammary chain lymph nodes described as "snowstorm
artifacts". Even though it remained unproven, the supraclavicular fluid aspirate could have potentially
contained silicone particles. Of note, the supraclavicular swelling resolved post treatment. It is important to
mention that silicone may be hard to identify by conventional light microscopy techniques in
histopathologic specimens and special stains may be needed and should be specifically requested [14]
It has been postulated that as the implant elastomer ages, silicone can trigger macrophage activation,
leading to further histiocytic reaction with siliconomas including at distant sites. Interestingly, our first
patient presented with immune-mediated necrotizing myopathy, a disease characterized by a scant
inflammatory infiltrate of a predominant monocytic lineage [15]. It is perhaps important to note the
proximity of the gluteal implants to thigh muscle extensors as well as the inflammatory infiltrate that was
aspirated from the periprosthetic area. Furthermore, multiple case reports of sarcoidosis induced by silicone
implants have been identified in the literature [16].
To our knowledge, this is the first case of AIHA associated with silicone implant rupture. In animal studies,
the injection of silicone gel in New Zealand Black (NZB) mice has led to the induction of proteinuria and
AIHA [17]. Furthermore, silicone-associated illness has been reported in patients with a specific genetic
predisposition, with vitamin-D deficiency, smokers, and patients with immunoglobulin deficiency [8,18].

Conclusions
Between questioning its existence to inconsistent naming and heterogenous presentation, silicone-induced
disease calls for a multidisciplinary approach, including plastic surgeons, immunologists, radiologists,
pathologists, and rheumatologists. This collaboration may further help close the gap in defining this
heterogenous group of manifestations, clinical presentation, pathogenesis, and nomenclature as well as
definitely prove causation. Proper identification of these patient groups through a multidisciplinary
approach before implantation may help with risk stratification. Management is also at the frontier of two
specialties. As illustrated in our first case, the patient continued to have symptoms despite silicone removal,
which correlates with findings in the literature that explantation alone does not lead to the reversal of the
disease process and that combined immunosuppressive therapy and prosthesis removal are vital in
treatment. Timing of surgical explantation as well as the use of immunosuppressive medications in view of
their potential deleterious postsurgical outcomes should be also a topic of collaboration between the
specialties. These findings further support the need for multidisciplinary management of these complex
patients.
Our article aims to continue increasing awareness and open the collaboration between plastic surgeons and
rheumatologists to treat potential cases of breast implant illness in a multidisciplinary manner. Risk
stratification preimplantation may further identify patients that are at risk of developing ASIA syndrome.
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